Project Grant K23HL188194
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $198K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $1,579,554 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 10, 2025, to conduct multi-trait, multi-ancestry, and multi-omic genetic studies of chronic obstructive pulmonary disease (COPD) and asthma using data integrated across global biobanks. The work integrates genetic and phenotypic data from the All of Us Research Program,...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $330,176 on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mentored research on the effect of severe obesity on regional lung perfusion in acute hypoxemic respiratory failure. The award funds two primary research aims. Aim 1 defines the association between severe obesity and regional lung perfusion in a novel...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $1,664,696 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an optical imaging biomarker for predicting disease progression and mortality risk in early idiopathic pulmonary fibrosis. The research develops a patient-specific optical biomarker measured through minimally-invasive endobronchial polarization-sensitive optical coherence...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital $247,500 under the Cardiovascular Diseases Research program (CFDA 93.837) to validate a positron emission tomography (PET) imaging probe targeting CD206-positive macrophages for idiopathic pulmonary fibrosis (IPF) diagnosis and monitoring. The project, which commenced August 15, 2025 and concludes July 31, 2027, aims to develop and validate a PET imaging agent that shares...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $185,196 on January 7, 2027 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a pilot multi-center cohort study examining patient and caregiver burden in chronic limb-threatening ischemia (CLTI). Aim 1 will assess how caregiver support relates to patient outcomes including quality of life, amputation, readmission, and mortality, collecting...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $247,500 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025 through August 31, 2027. The award supports research to develop a non-invasive biomarker-based classifier model for early detection of pulmonary vascular dysfunction (PVD) in acute respiratory distress syndrome (ARDS) patients. ARDS patients with PVD...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $802,156 under Project Grant R01HL183169 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of diffusion tensor magnetic resonance imaging (DTI) techniques to image the microstructure of the human right ventricle in vivo. The recipient will develop a diffusion-encoded MRI sequence compensated for...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $121,345 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026. The award funds development of positron emission tomography (PET) imaging of oxidized collagen as a biomarker for myocardial fibrosis in heart failure with preserved ejection fraction (HFpEF). The project focuses on targeted PET imaging probes that bind...
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytesā€”specialized mural cells that maintain capillary stabilityā€”transition into smooth muscle-like cells under...